[{"orgOrder":0,"company":"GH Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GH Research Completes Phase 1 Clinical Study with GH001 in Healthy Volunteers and Updates on Further Progress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"GH Research Announces Closing of $125 Million Oversubscribed Series B Financing","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"GH Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by GH Research
GH001, is formulated for mebufotenin (5-MeO-DMT) administration via a proprietary inhalation approach, which is investigated for the treatment of treatment-resistant depression.
GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.
GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the investigated dose levels.